The present invention belongs to the field of therapeutic treatments of cancer diseases, particularly solid tumors such as melanoma, cancers of the gastrointestinal tract and thyroid carcinoma. The use of a melanocortin 4 receptor antagonist offers a possible new target therapy in the treatment of cancer diseases, counteracting the possibility of recurrence.
Research Institution:
Università di Pisa
